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Abstract. CIGB‑300 is a novel clinical‑stage synthetic peptide 
that impairs the casein kinase 2 (CK2)‑mediated phosphoryla‑
tion of B23/nucleophosmin in different experimental settings 
and cancer models. As a single agent, CIGB‑300 induces apop‑
tosis in vitro and in vivo and modulates an array of proteins that 
are mainly involved in drug resistance, cell proliferation and 
apoptosis, as determined by proteomic analysis. However, the 
clinical oncology practice and cumulative knowledge on tumor 
biology suggest that drug combinations are more likely to cope 
with tumor complexity compared to single agents. In this study, 
we investigated the antiproliferative effect of CIGB‑300 when 
combined with different anticancer drugs, such as cisplatin 
(alkylating), paclitaxel (antimitotic), doxorubicin (antitopoi‑
somerase II) or 5‑fluorouracil (DNA/RNA antimetabolite) in 
cell lines derived from lung and cervical cancer. Of note, using 
a Latin square design and subsequent analysis by CalcuSyn 
software, we observed that paclitaxel and cisplatin exhibited the 
best synergistic/additive profile when combined with CIGB‑300, 
according to the combination and dose reduction indices. Such 
therapeutically favorable profiles may be explained by a direct 
cytotoxic effect and also by the observed cell cycle impair‑
ment following incubation of tumor cells with selected drug 
combinations. Importantly, on in vivo dose‑finding schedules in 
human cervical tumors xenografted in nude mice, we observed 
that concomitant administration of CIGB‑300 and cisplatin 
increased mice survival compared to single‑agent treatment. 
Collectively, these findings provide a rationale for combining the 
anti‑CK2 CIGB‑300 peptide with currently available anticancer 
agents in the clinical setting and indicate platins and taxanes as 
compounds with major perspectives.
Introduction
The implication of constitutive and often exacerbated enzy‑
matic activity of casein kinase 2 (CK2) in the maintenance 
of the malignant phenotype has been firmly established by 
in vitro and in vivo preclinical experimentation and epide‑
miological findings in several types of tumors (1,2). Based 







new‑generation anti‑CK2 compounds are ultimately repre‑
sented by CX‑4945, a small‑molecule adenosine triphosphate 
(ATP) competitor currently  in clinical cancer  trials  (9,10). 
Focusing on the same tumor‑specific CK2 signaling but 
aiming to abrogate such events by binding to the phosphoa‑
ceptor domain on its substrates, the CIGB‑300 peptide was 
discovered by screening a phage display library against a 
model CK2 substrate (11).
In different experimental settings and preclinical cancer 
models, CIGB‑300 was shown to inhibit the CK2‑mediated 
phosphorylation of the validated CK2 substrate B23/nucleo‑
phosmin,  leading  to a  fast cell death by apoptosis  (12,13). 
However, considering the high degree of conservation for 
the CK2 phosphoaceptor domain, a multitarget effect may be 
anticipated (14). Such a multitarget effect may better explain the 
diverse arrays of proteins and processes that appear to be modu‑
lated by CIGB‑300 and its already established antiangiogenic 
effect (15,16). Of note, CIGB‑300 exerts a broad antiprolif‑
erative effect on cell lines derived from breast, cervical, lung, 
colon and prostate cancer, while a robust antitumor effect 
was also observed in vivo in mouse models of cervical and 
lung cancer (13,17,18). In the clinical setting, CIGB‑300 was 
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investigated in a phase I clinical trial on high‑grade squamous 
intraepithelial lesions (HSILs), establishing its safety and 
tolerability by  local  injection  (19). More  recently,  another 
phase I clinical study on patients with stage 1B2/II cervical 
cancer allowed us to estimate the maximum tolerated dose 
(MTD) and the pharmacokinetics̸biodistribution profiles for 
CIGB‑300 following local administration (20). Moreover, 
a phase I study on lung and haematological cancers further 
demonstrated that CIGB‑300 may also be administered by 
intravenous injection without significant toxicity (unpublished 
data). Of note, the first evidence regarding the antitumor effect 
of CIGB‑300 in humans was recently collected from case 
studies (21).
Despite these promising preclinical and clinical findings 
using the CIGB‑300 peptide, the clinical oncology setting and 
cumulative knowledge on cancer biology suggest that drug 
combinations are more likely to cope with tumor complexity 
compared to single agents (22). Of note, previous data from 
proteomics studies demonstrated that CIGB‑300 modulates 
a group of proteins directly involved in anticancer drug 
resistance  (15). Therefore,  in  this  study, we evaluated  the 
antiproliferative effect of CIGB‑300 when combined with 
four different chemotherapeutics drugs in two model cell lines 
derived from lung and cervical cancer. With the aim to select 
the optimal combination in these two clinically relevant tumor 
types, the peptide was combined in a pairwise manner with 
anticancer drugs, such as antimitotic (paclitaxel), alkylating 
(cisplatin), antitopoisomerase II (doxorubicin) or DNA̸RNA 
antimetabolite (5‑fluorouracil) agents. Based on the estimation 
of the combination index (CI) (23), all the interactions were 
classified as synergistic, additive or antagonistic and the direct 
effect on cell viability and proliferation was analyzed. Finally, 
the potential benefit of one selected drug combination over 
each monotherapy was corroborated in vivo in a mouse model 
of cervical cancer.
Materials and methods
Cell lines and chemotherapeutic agents. The NCI‑H125 
non‑small‑lung cancer cell line and the SiHa cervix‑derived 
squamous carcinoma cell line were originally acquired from 
American Type Culture Collection (Manassas, VA, USA) and 
cultured  in RPMI or Dulbecco's modified Eagle's medium 
supplemented with 10% fetal bovine serum, unless otherwise 
stated. The clinical grade chemotherapeutic drugs paclitaxel, 
cisplatin, doxorubicin and 5‑fluorouracil (Drug Research and 
Development Center, Havana, Cuba) were kindly provided by 
the Oncology Service of the National Institute of Oncology 
and Radiobiology (Havana, Cuba) or from the Hermanos 
Ameijeiras Hospital (Havana, Cuba).
CIGB‑300. The CIGB‑300 peptide was synthesized on solid 
phase, purified by reverse‑phase high‑performance liquid 
chromatography to >98% purity on acetonitrile/H2O‑triflu‑
oroacetic acid gradient and confirmed by ion‑spray mass 
spectrometry (Micromass, Manchester, UK).
Drug combination assays. The  48‑h  sulforhodamine  B 
(SRB)‑based assay was adopted from the National Cancer 
Institute to measure the cytotoxic effect of each drug 
combination (24). Sulforhodamine B sodium salt was purchased 
from Sigma‑Aldrich (St. Louis, MO, USA). NCI‑H125 or SiHa 
cell suspensions (6x104 cells̸ml) were seeded on 96‑well plates 
(Corning Costar; Sigma‑Aldrich, ) and on the next day, a curve 
of serial dilutions for each compound (1:2 or 1:10 on RPMI) 
were added and incubated for 48 h. Following plate reading, the 
data were analyzed by the CalcuSyn software, which is based 
on the median effect equation (23,25). The type of interaction 
was scored as synergistic, additive or antagonistic, according 
to the obtained CI. The interaction maps were represented by 
color‑coded surfaces rendering a 3D visual effect within a 
2D plot. The maps were built by superimposing filled contours 
(CI) and isoline plots (Fa, fraction affected), partially scripted 
with Matlab® R2012a software (7.14.0.0739; http://www.math‑
works.com/).
Cytotoxicity by propidium iodide (PI) exclusion. NCI‑H125 
or SiHa cells were seeded at 6x104 cells/ml on 24‑well culture 
plates (Corning Costar) and incubated for 24 h. On the next 
day, selected concentrations of CIGB‑300, paclitaxel, cisplatin, 
or their combinations, were added to the plates and incubated 
for 0.5, 2, 5, 8, 24 and 36 h. The cells were  subsequently 
washed with cold phosphate‑buffered saline (PBS) and stained 
for 10 min with 5 µg/ml PI solution. Finally, the stained cells 
were analyzed on the FL2 channel using the Partec PAS III 
particle analyzing system flow cytometer and their proprietary 
FloMax v2.4f software (Partec GmbH, Münster, Germany).
Cell cycle analysis. The cell cultures were incubated with 
selected concentrations of CIGB‑300, paclitaxel, cisplatin, 













Laboratories  GmbH,  Eystrup,  Germany̸National  Atomic 
Energy Commission, Buenos Aires, Argentina) were injected 
subcutaneously  in  the right flank with 4x106 SiHa cells in 
300 µl PBS. When the tumors reached 30 mm3, the mice were 
randomly assigned into 7 groups (n=4 per group) and were 
administered placebo, CIGB‑300 (days 1‑5, 50 or 200 µg), 
cisplatin (days 1, 3 and 5, 1 or 4 mg/kg), or their combinations, 
by intraperitoneal (cisplatin) or intratumoral (CIGB‑300) 
routes.
Scheme B. A total of 35 8‑week‑old female nude mice 
(Harlan Laboratories GmbH/National Atomic Energy 
Commission) were injected with 3x106 SiHa cells as described 
for scheme A. When the tumors reached 30 mm3, the mice 
were randomly assigned into 7 groups (n=5 per group) and 
injected with placebo, CIGB‑300 (days 1‑5, 100 or 200 µg), 
cisplatin (days 1, 3 and 5, 3 or 6 mg/kg), or their combinations, 
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by the routes indicated in scheme A. The tumors were 
measured every other day with a caliper and their volumes 
were calculated as follows: volume = length x width2/2. 
Survival was daily registered during the experimentation, 
unless the tumor volumes reached 2,000 mm3, in which case 
the animals were sacrificed due to ethical considerations. 
The mice were maintained under pathogen‑free conditions 
and all the procedures were performed in accordance with 
the recommendations for the proper use and care of labo‑
ratory animals at the Center for Genetic Engineering and 
Biotechnology (Havana, Cuba).
Statistical analysis. The tumor volumes among the different 
groups were compared using one‑way analysis of variance 
(ANOVA) and Tukey's post hoc test. The log‑rank test was 
applied for the survival analysis of the Kaplan‑Meier curves. 
All the statistical analyses were performed using GraphPad 
Prism version 4.00 for Windows (GraphPad Software, 
San Diego CA, USA).
Results
Antiproliferative effect of CIGB‑300 and chemotherapeutic 
drugs as single agents. In order to select a suitable range of 
drug concentrations for combination experiments, we first 
evaluated the antiproliferative effect of CIGB‑300 and four 
different chemotherapeutics drugs used in the treatment of 
lung (paclitaxel and cisplatin) and cervical cancer (paclitaxel, 
cisplatin, doxorubicin and 5‑fluorouracil) with the SRB‑based 
assay (Fig. 1).
The fitting of each curve to the median effect equa‑
tion allowed us to estimate the half maximal inhibitory 
drug concentration (IC50), also referred to as drug potency, 
and the steepness or shape of the curve for each individual 
Table I. Drug potency (IC50) and steepness (m) of the dose‑response curves obtained after fitting the SRB‑based assay data to the 
median effect equation using the CalcuSyn software.
  NCI‑H125 cells SiHa cells
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
  IC50  Drug range IC50  Drug range
Compound Class  (µM)  m  (µM)  (µM)  m  (µM)
CIGB‑300 CK2‑targeted therapy  69.80  1.60  6.25‑200  91.10  1.17  12.5‑400
Paclitaxel  Antimitotic  0.03  0.13  0.00002‑2  0.01  0.13  0.0002‑2
Cisplatin  Alkylating  9.43  2.38  0.31‑10  6.61  0.96  1.56‑25
Doxorubicin  Antitopoisomerase II  0.14  0.76  0.00025‑25  0.13  0.35  0.00025‑25
5‑Fluorouracil  RNA/DNA antimetabolite  17.83  0.40  0.02‑2000  1.28  0.11  0.02‑200
The classification of each anticancer compound and the selected range of concentrations for further combinations experiments are also shown. 
SRB, sulforhodamine B; CK2, casein kinase 2; IC50, half maximal inhibitory concentration.
Figure 1. Antiproliferative dose‑response curves for CIGB‑300 and chemotherapeutic drugs assessed as single agents in the (A) NCI‑H125 lung cancer and 
(B) SiHa cervical cancer cell lines. The curves were generated by fitting the data derived from the sulforhodamine B‑based assays to the median effect equation 
using the CalcuSyn software. The quality of the fitting was assessed by the r coefficient, where an r>0.9 was obtained for all curves. 5‑FU, 5‑fluorouracil.
  A   B
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drug (m) (Table I). As expected, due to the diverse nature and 
mechanism of action of the tested compounds, the results 






the combination experiments to cover an extensive range of 
cytotoxic effects.
Drug combination experiments. To determine the type of 
interaction (i.e., synergistic, additive or antagonistic) between 
the CIGB‑300 peptide and conventional chemotherapeutic 
drugs in the two tumor types, we used the CalcuSyn software. 
A Latin square design was selected to investigate such interac‑
tions across a range of different drug concentrations, which 
included clinically achievable drug levels. Representative 
examples of the graphs generated from the analysis of two 
particular drug combinations, i.e., CIGB‑300 plus paclitaxel 
in NCI‑H125  cells  (non‑constant  ratio  combinations)  and 
CIGB‑300 plus cisplatin in SiHa cells (constant‑ratio combina‑
tions), are shown in Fig. 2.
To visualize the results obtained from all 8 combination 
experiments (i.e., CIGB‑300 pairwise combined with 4 drugs 
in 2 cell lines), an interaction surface was built by representing 
in a color code the estimated CI for each particular pair of drug 
combinations (i.e., 6x6 concentration matrix) (Figs. 3 and 4). 
Moreover, in order to assess the actual relevance of the observed 
interaction pattern, we also represented the Fa by the combina‑
tions over this 2D graphical display of interaction data.
The results of the combination experiments in the 
SiHa cervical cancer cell line demonstrated that CIGB‑300 
interacts  synergistically with  paclitaxel  in  >50%  of  the 
interaction  surface, with  effect  levels  or  Fa>60% of  the 
cell population, while only small areas of antagonism were 
registered at extreme concentrations (i.e., low for both 
drugs or very high for paclitaxel) (Fig. 3A). A similar but 
less promising interaction pattern was observed for the 
combination of CIGB‑300 plus doxorubicin, where regions 
of additive or slight antagonism between the two drugs were 
found to be more predominant at higher effect levels (>50%) 
when the concentration of doxorubicin increased (Fig. 3C). 
An intermediary scenario was observed for the combination 
of CIGB‑300 plus cisplatin, with >70% of  the  interaction 
surface exhibiting an additive pattern even at high effect 
levels (40‑85%) (Fig. 3B). The worse combination scenario 
was clearly observed for the CIGB‑300 plus 5‑fluorouracil 
combination, where a strong antagonism was observed in 
approximately half of the interaction surface, with syner‑
gistic interaction areas only seen at very high concentrations 





pattern in lung and cervical cancer cells was observed for 
the combination of CIGB‑300 plus cisplatin, with significant 
areas of the interaction surface exhibiting an additive pattern 
at effect levels >60% (Fig. 4B). Finally, a moderate (CI>1.20) 
to strong antagonism (CI>3.3) was observed practically 
across the entire interaction surface when the combinations of 
CIGB‑300 plus doxorubicin and CIGB‑300 plus 5‑fluorouracil 
were evaluated in NCI‑H125 cells (Fig. 4C and D).
Another important output derived from the analysis of 
drug interaction data using CalcuSyn is the dose reduction 
Figure 2. Graphs generated by the CalcuSyn software using the fraction affected (Fa) vs. concentration data for each drug alone or its combinations in the 
NCI‑H125 (CIGB‑300 plus paclitaxel) and SiHa (CIGB‑300 plus cisplatin) cell lines. (A and C) Dose‑response curves obtained for each drug or its combinations 
at non‑constant ratios using a fixed concentration of paclitaxel (0.02 µM) in NCI‑H125 cells (A), or at constant ratios among the drugs (CIGB‑300:cisplatin, 4:1) 
in SiHa cells (C). (B and D) CI vs. Fa graphs for the combinations described in (A and C), respectively. Pacltx, paclitaxel; CDDP, cisplatin; CI, combination index.
  A   B
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Figure 3. Interaction surface built using the estimated combination index (CI) for each combination experiment comprising the CIGB‑300 peptide and the 
chemotherapeutic drugs (A) paclitaxel, (B) cisplatin, (C) doxorubicin, or (D) 5‑fluorouracil (5‑FU) in the SiHa cervical cancer cell line. The CI was calculated 
with the CalcuSyn software for each particular drug combination and represented in 2D color code graphics or interaction surface. The color code spans 
from strong synergism (dark blue, CI<0.30) to strong antagonism (red, CI>3.3). The graphics also include the fraction affected (Fa; expressed in %) by each 
combination across such an interaction surface (dotted line on top). The concentrations of each particular drug in the combinations are denoted on each axis.
Figure 4. Interaction surface built using the estimated combination index (CI) for each combination experiment comprising the CIGB‑300 peptide and the 
chemotherapeutic drugs (A) paclitaxel, (B) cisplatin, (C) doxorubicin, or (D) 5‑fluorouracil (5‑FU) in the NCI‑H125 lung cancer cell line. The graphics show 
the fraction affected (Fa) by each combination across such an interaction surface and the concentrations of each particular drug in the combinations.
  A   B
  C   D
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index (DRI). This parameter is inversely associated with CI 
and represents the number of times each single drug may 
be reduced in a combination setting without compromising 
the final therapeutic effect (23). The estimated DRI from 
the combination of CIGB‑300 plus paclitaxel indicated that, 
in a synergistic scenario like those exemplified in Table II, 
5‑fold less peptide (DRI=5.3) is required to achieve an 
antiproliferative  effect  level  of  94%  in  NCI‑H125  cells 
(Fa=0.94). Furthermore, in the same combination setting, 
the concentration of paclitaxel may be reduced 3,250 times 
without compromising the final antiproliferative effect in lung 
cancer cells (Table II). A significant DRI was also achieved 
in the combination of CIGB‑300 plus cisplatin for the peptide 
(DRI=8.5) but not for cisplatin, where only a small DRI was 
observed (DRI=1.2) (Table II). As expected, in the majority of 
the combination experiments where a synergistic pattern was 
observed, important DRIs were registered for all the drugs 
(data not shown).
Effect of drug combinations on cell cycle and viability. The 
characterization of the type of interaction performed thus far 
was based on a global proliferative readout (i.e., cell mass 
staining) from the SRB‑based assay. To evaluate how selected 
drug combinations affect cell proliferation and viability, 
we measured the DNA content and the loss of cytoplasmic 
membrane integrity as indicators of cell cycle progression 
and cell cytotoxicity, respectively. Two particular synergistic 
drug combinations, namely CIGB‑300 plus paclitaxel in lung 
cancer cells and CIGB‑300 plus cisplatin in cervical cancer 
cells, were selected for the analysis (Table II, Figs. 3 and 4).
The effect of the combination of CIGB‑300 plus paclitaxel 
on cell cycle progression in lung cancer cells was determined 
Table Ⅱ. Parameters estimated using the CalcuSyn software for two selected combinations of CIGB‑300 plus chemotherapy in 
NCI‑H125 and SiHa cells.
 Combination Parameters DRI
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
   IC50   Interaction
Cell line  Drugs  (µM)  (µM)  CI  Fa  type  Drug 1  Drug 2
NCI‑H125  CIGB‑300 + paclitaxel  75+0.02  0.03  0.30  0.94  Strong synergism  5.3  3250
SiHa  CIGB‑300 + CDDP  25+12.5  6.61  0.83  0.73  Moderate synergism  8.5  1.2
CDDP, cisplatin; IC50, half maximal inhibitory concentration; CI, combination index; Fa, fraction affected; DRI, dose reduction index.
Figure 5. Effect of selected drug combinations on (A) cell cycle progression and (B and C) cell viability of NCI‑H125 and SiHa cells. (A) The DNA content 
from treated and untreated NCI‑H125 cells was assessed by flow cytometry using the FloMax software. The percentages refer to the difference between 
non‑treated and treated cells at particular cell cycle phases (normalization). (B and C) Cytotoxicity was determined by flow cytometry using propidiun iodide 
(PI) as a vital stain. NCI‑H125 or SiHa cells were incubated for 0.5‑36 h with each drug alone or its combinations at the concentrations described in Table II; 
the cells were then stained with PI and analyzed by flow cytometry.
  A   B
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using PI to stain genomic DNA. After gating out cellular 
debris and excluding cell doublets, the DNA distribution was 
fitted to a diploid DNA content for cell cycle profiling. The 
analysis demonstrated that both CIGB‑300 and paclitaxel 
cause a cell cycle arrest in the G2/M phase of the cell cycle 
(15 and 46%, respectively), while their combination caused 
cell  cycle  arrest  at  the  S  (27%)  and G2/M  (15%)  phases 
(Fig. 5A). Of note, in SiHa cells, CIGB‑300 at 25 µM did not 
affect the cell cycle distribution, whereas cisplatin and the 
combination caused only a mild arrest at the S phase (10%) 
(data not shown).
As regards the cytotoxicity of the selected drug combina‑
tions, the results obtained with the combination of CIGB‑300 
plus paclitaxel in lung cancer cells corroborated the previously 
observed synergistic interaction. We observed a stronger cyto‑
toxic effect for the combination compared to the one registered 
for each drug alone, which was more evident after 24 and 36 h 
of incubation (Fig. 5B). This kinetic experiment also revealed 
that, while paclitaxel‑induced cytotoxicity increases gradually 
from 2 to 36 h, the effect of CIGB‑300 may be seen as early 
as 0.5 h, reaching a maximum effect between 5 and 8 h and 
after 36 h. Finally, the cytotoxic effect of CIGB‑300 alone at 
25 µM was found to be negligible in the SiHa cervical cancer 
cell line compared to that of cisplatin alone or its combination 
with CIGB‑300 (Fig. 5C).
In vivo drug combination in a cervical cancer animal 
model. To corroborate the potential benefit of combining the 
CIGB‑300 with chemotherapy in vivo, we evaluated the effect 
of simultaneous administration of the peptide and cisplatin 
on tumor growth and survival following the inoculation of 
SiHa cells in nude mice. In both experiments (schemes A 
and B), the doses for each single agent and its combinations 
were selected to maintain a fixed ratio among the drugs 
to further evaluate the type of interaction by CalcuSyn. In 
scheme A (CIGB‑300:cisplatin, 2.5:1),  the single agents as 
well as their combination significantly reduced tumor growth 
(>60%  inhibition, T/C 0.4‑0.2,  day 37)  and  increased  the 
survival of treated mice (4‑13 days) in this cervical cancer 
model (Fig. 6A and B)
Of note, in this experimental setting, the lower dose combi‑
nation of CIGB‑300 plus cisplatin achieved a more significant 
tumor growth delay and survival compared to each mono‑
therapy alone (Fig. 6A insert and Fig. 6B). At day 37, the group 
treated with this combination (CIGB‑300 50 µg plus cisplatin 
1 mg/kg) resulted in 77% tumor growth inhibition (T/C=0.23), 
while the corresponding monotherapies achieved a less 
significant effect (CIGB‑300: 63% inhibition, T/C=0.37; and 
cisplatin: 68% inhibition, T/C=0.32) (Fig. 6A insert). However, 
no significant differences were observed between such groups 
(one‑way ANOVA, Tukey's post hoc test). The superiority 
regarding the tumor growth inhibition of combining the 
higher  doses  of  each  compound  (CIGB‑300  200  µg  plus 
cisplatin 4 mg/kg) was rather subtle, as a consequence of the 
strong effect of cisplatin alone (80% vs. 79%, respectively) 
(Fig. 6A). By contrast, the survival analysis indicated that the 
combination of the lower doses of CIGB‑300 and cisplatin 
significantly increased the survival (5.5 days) of tumor‑bearing 
mice compared to each monotherapy alone (combina‑
tion vs. CIGB‑300, P<0.05; combination vs. cisplatin, P<0.01), 
whereas the higher dose combination prolonged survival up 
to 8 days over each single agent (combination vs. CIGB‑300, 
P<0.01;  combination  vs.  cisplatin, P<0.01)  (log‑rank  test) 
(Fig. 6B).
In scheme B (CIGB‑300:cisplatin, 1.7:1), although both 
single agents and their combinations exerted a potent antitumor 
Figure 6. Antitumor effect of CIGB‑300, cisplatin (CDDP) or their combinations, in a cervical cancer model based on the inoculation of SiHa cells in nude 
mice. Once the tumor mass reached 30 mm3 (day 0), the mice were randomized into groups and injected with CIGB‑300, cisplatin or their combinations at 
indicated doses, according to schemes A and B described in Materials and methods. (A and B) Tumor growth and Kaplan‑Meier survival curves obtained from 
treated animals in scheme A. (C and D) Tumor growth and survival curves obtained from treated animals in scheme B.
  A   B
  C   D
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effect (>70% inhibition, T/C 0.25‑0.17, day 31), the differences 
in tumor growth inhibition for monotherapies compared to 
combination treatments did not reach statistical significance 
(Fig. 6C insert). However, the survival analysis indicated that 
the lower dose combination (CIGB‑300 100 µg plus cisplatin 
3 mg/kg) prolonged mouse survival at least by 9 days compared 
to each monotherapy alone (P<0.05) (Fig. 6D).
Discussion
CIGB‑300 is a novel clinical stage molecule designed to impair 
CK2‑mediated phosphorylation by binding to the conserved 
phosphoaceptor domain on its substrates (11). The antineo‑
plastic effect of this peptide has been well documented in the 
preclinical setting in vitro and in vivo (13,17,18). In 2006, the 
peptide entered a phase I clinical trial on patients with HSILs, 
where safety and efficacy signs were registered (19). More‑
over, in patients with stage 1B2/II cervical cancer, the MTD, 
biodistribution and modulation of a response biomarker were 
investigated following local administration of CIGB‑300 (20). 
Finally, evidence of the antitumor activity of CIGB‑300 in 
humans was recently collected from case studies (21).
Although preclinical and clinical findings support the use of 
the CIGB‑300 peptide as a monotherapy, it is widely accepted 
that the combination of drugs in the field of oncology are more 
likely to cope with tumor complexity compared to single‑agent 
treatment (22). Such a view is sustained by decades of clinical 
practice and by cumulative knowledge on tumor biology (26). 
Drug combination therapies are commonly used in order to 
increase therapeutic efficacy, reduce toxicity and decrease the 
incidence of drug resistance. In this scenario, the combina‑
tion of targeted therapies plus conventional chemotherapy 
has emerged as an alternative therapeutic option that requires 
further investigation (27).
To the best of our knowledge, the antineoplastic effect of 
the CIGB‑300 peptide when combined with different chemo‑
therapeutic drugs currently used in the treatment of lung and 
cervical cancer was first investigated in this study. The drugs 
used included antimitotic and DNA alkylating agents, topoi‑
somerase II inhibitors and DNA/RNA antimetabolites, hence 
targeting different global cellular processes. In order to avoid 
false claims of synergism commonly found in the literature, 
we performed our interaction studies using the CalcuSyn soft‑
ware, which is based on the median effect equation described 
by Chou (23). One of the main advantages of this analysis over 
the classical isobologram is that the type of interaction can 
be scored through an entire range of drug combinations and 
effect levels once a Latin square design is selected. Of note, 
in order to visualize all interaction data at the same time, a 
simple script was built to draw an interaction surface. On such 
an interaction surface, additional representation of the effect 
level allowed us to better assess the relevance of the observed 
interaction pattern ‘at a first glance’. Indeed, synergistic inter‑
actions at low effect levels (e.g., Fa<0.4) may be less relevant 




Our in vitro interaction studies suggested that the 
anti‑mitotic drug paclitaxel may be a suitable partner to 
combine with CIGB‑300 in lung and cervical malignancies. A 
plain synergistic interaction was observed in most of the inter‑
action surface from NCI‑H125 and SiHa cells. Importantly, 
such synergistic  interaction resulted  in >70% proliferation 




outcome, hence limiting the chances of unwanted side effects. 
This issue is of paramount importance in the case of paclitaxel, 
a drug known to be associated with significant toxicities, such 
as myelosuppression and peripheral neuropathy (28).
The combination of CIGB‑300 with the alkylating drug 
cisplatin displayed an additive interaction pattern across most 
of the interaction surface in SiHa cells. Of note, for paclitaxel 
and cisplatin, further combination experiments demonstrated 
that the simultaneous addition of CIGB‑300 and the chemo‑
therapeutic agent is more favorable compared to their sequential 
addition, according to schedule‑dependent experiments (data 
not shown). Altogether, while the combination of the CIGB‑300 
peptide with the antimitotic drug paclitaxel appears to be 
more favorable for lung cancer treatment, the combination of 
CIGB‑300 with cisplatin may be more promissory in cervical 
cancer. Considering that paclitaxel and cisplatin are chemo‑
therapeutic drugs currently used for the treatment of lung and 
cervical cancer, respectively, the evaluation of these particular 
drug combinations in their already approved clinical niches 
may be more expedite. However, a quite different profile was 
obtained from combining CIGB‑300 with doxorubicin in lung 
and cervical cancer cells. In lung cancer cells, the combina‑
tion of CIGB‑300 with the topoisomerase II inhibitor and with 
DNA/RNA antimetabolites, resulted in antagonistic surfaces 
with rather scarce areas of additive or synergistic effects under 
these experimental conditions.
A further layer of analysis in drug combination experiments 
is whether drug concentrations resulting in a synergistic inter‑
action are actually achievable in vivo. The pharmacokinetic 
analysis of CIGB‑300 in animal models and humans indicated 
that this peptide may reach concentrations up to 30 µM in the 
plasma, whereas after a 3‑h infusion of paclitaxel at doses of 
135‑225 mg/m2 the estimated Cmax ranged between 3.3 and 
7.6 µM. (unpublished results; 29). According to such reported 
values, a significant area of the synergistic interaction between 
these two drugs occurs in the range of clinically achievable 
concentrations. Importantly, a similar analysis also suggested 
that the predominant additive profile obtained from the 
combination of CIGB‑300 plus cisplatin in cervical cancer 
cells occurs in a concentration range achievable in vivo for 
CIGB‑300 (<30 µM) and cisplatin (<15 µM) (30,31).
Considering that in the in vivo setting precise drug concen‑
trations or ratios are difficult to achieve (32), broad favorable 
interaction surfaces in vitro (i.e., synergistic or additive) may 
suggest a higher chance of obtaining an antitumor effect at the 
organism level, both in mouse models and hopefully the clinical 
setting. Likewise, such favorable profiles provide us with more 
confidence to exclude potential antagonism arising from drug 
combinations at particular ratios or concentrations. Following 
this rationale and taking into account that cervical cancer is 
one of the clinical niches where CIGB‑300 is currently being 
evaluated as a monotherapy (20), we attempted to corroborate 
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the potential therapeutic benefit of combining CIGB‑300 
with cisplatin in vivo after inoculating human cervical cancer 
cells in nude mice. Although such experiments were initially 
designed to be analyzed by CalcuSyn, the reduction of tumor 
growth with monotherapies and drug combinations were far 
above the IC50 in all cases (T/C<0.5), thus precluding the 
generation of reliable dose‑response curves for CI determina‑
tion (23). However, our results demonstrated that two different 
CIGB‑300 plus cisplatin combinations (i.e., different doses 
and drug ratios) significantly increased animal survival when 
compared to each monotherapy alone. Such in vivo results are 
in complete accordance with the broad additive interaction 
surface observed with the concentration range and drug ratios 
evaluated in vitro in the antiproliferative setting.
Although drug combination experiments may be 
performed over days or weeks, the elucidation of the cellular 
and molecular basis underlying the observed interactions typi‑
cally requires years of research. The analysis at the cellular 
level for one particular drug combination (i.e., CIGB‑300 plus 
paclitaxel) in lung cancer cells indicated that the observed 
synergistic interaction arose from their effect on cell cycle 
progression and viability. However, only cytotoxicity appeared 
to contribute to the observed synergism regarding the combi‑
nation of CIGB‑300 plus cisplatin in cervical cancer cells, 
suggesting that particular drug combinations affect cell prolif‑
eration at different levels.
The first molecular clues that may explain the synergistic 
interaction with anticancer drugs in lung cancer cells were 
previously revealed by proteomics analysis of CIGB‑300‑treated 
NCI‑H125 cells (15). In such studies, the peptide modulated an 
array of proteins associated with drug resistance and survival, 
which may favor the cytotoxic effect of several chemothera‑
peutic drugs. One of the downregulated proteins was found to 
be the nuclease‑sensitive element‑binding protein 1 (YB‑1), a 






in the nucleotide excision repair pathway and plays a role in 
cisplatin‑DNA adduct reparation (35); therefore, its downregu‑
lation may also account for the observed additive pattern in the 
combination of CIGB‑300 plus cisplatin. Intriguingly, although 
YB‑1 is a validated substrate for CK2 (36), this protein does 
not interact with CIGB‑300 according to previous pull‑down 
experiments conducted on lung cancer cells (12).
CIGB‑300 was also shown to decrease the levels of gluta‑
thione S‑transferase Pi (GST‑Pi), a cytoplasmic detoxifying 
enzyme, whose increased levels correlate with resistance to 
a wide range of drugs (37). Although paclitaxel and cisplatin 
are not direct substrates for this enzyme, both drugs require 
the activation of the MAP kinase pathway to exert their 
maximal cytotoxicity, which is prevented by high levels of 
GST‑Pi. Moreover, at least three other proteins associated with 
drug resistance were clearly downregulated by CIGB‑300 in 
NCI‑H125 cells (15). Whether the synergistic/additive interac‑
tion patterns observed with the combination of CIGB‑300 with 
cisplatin or paclitaxel may be explained by these molecular 
events require elucidation by further studies.
Despite the availability of a significant number of studies 
on CK2, the number of reports on the use of CK2 inhibitors in 
combination with anticancer compounds remains limited (38). 
Such pioneering studies mainly rely on the genetic manipu‑
lation of the catalytic subunit CK2α or  the use of  the first 
‑generation semi‑selective CK2 inhibitors DRB and TBB (38). 
Although these former studies provided valuable preclinical 
data, only with the advent of clinical‑grade inhibitors the 
true potential of combining anti‑CK2 approaches with 
conventional or emerging therapies may be translated into 
clinical grounds. Apart from the CIGB‑300 peptide, only the 
ATP‑competitive inhibitor CX‑4945 has been evaluated in 
humans as an anti‑CK2 therapy (9,10). A synergistic pattern 
for particular drug concentrations or ratios was reported when 
CX‑4945 was combined with different compounds targeting 
the  phosphatidylinositol  3  kinase  (PI3K)̸Akt̸mammalian 
target of rapamycin (mTOR) signaling axis in breast or lung 
preclinical cancer models (39,40). Considering that CK2 
phosphorylates critical substrates in this pathway (e.g., Akt, 
phosphatase and tensin homolog, p70SK6), the rationale behind 
such combination experiments was to reinforce the inhibi‑
tory effect of compounds such as erlotinib (epithelial growth 
factor receptor), LY294002 (PI3K) or the dual inhibitor PI‑103 
(PI3K and mTOR). Moreover, the combination of CX‑4945 
with cisplatin also resulted in a synergistic drug interaction in 
two ovarian cancer cell lines according to the Bliss additivity 
method (41,42). Beyond the fact that the methods of drug inter‑
action analysis differ, those studies only evaluated particular 
drug concentrations in vitro, without providing an explanation 
for its selection or investigating a wide range of concentrations 
for each of the compounds (39,41).
As a novel approach to impair the CK2‑mediated signaling, 
we investigated the potential therapeutic benefit of combining 
the CIGB‑300 peptide with different cytotoxic compounds 
targeting global cellular processes, which are firmly estab‑
lished in clinical oncology. Although we are currently focused 
on the elucidation of the molecular and cellular basis of 
observed synergistic/additive interactions, the preclinical 
data provided in this study may pave the way for near‑future 
clinical trials investigating the combination of the CIGB‑300 
peptide with conventional chemotherapeutic agents, such as 
paclitaxel and cisplatin in two frequent human cancers.
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